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Surfactant therapy restores gas exchange in lung injury due to 
paraquat intoxication in rats
K.L. So*, E. de Buijzer*, D. Gommers*, U. Kaisers+, P.J.J. van Genderen‡, B. Lachmann*
Since 1962, paraquat (1,1'-dimethyl-4,4'-bipyridylium
dichloride) has been widely used as a herbicide that is safe
during normal use but causes severe, often fatal lung dam-
age following accidental or experimental poisoning in a var-
iety of animals [1] and humans [2], regardless of the route
of administration. Paraquat preferentially causes lung toxic-
ity, resembling acute respiratory distress syndrome, ending
in either multiple organ failure or progressive lung fibrosis.
Until now, the rationale for treatment has concentrated
on preventing progression to pulmonary fibrosis, limiting
absorption from the gastrointestinal tract and enhancing
elimination from the systemic circulation; however, no
putative treatments of paraquat poisoning have proven cli-
nical efficacy and as a consequence, the mortality rate re-
mains high [3]. Thus, alternative treatment rationales have
to be examined.
Lung damage following paraquat poisoning appears to
be secondary to a derangement of pulmonary surfactant
[4–7], probably resulting not only from the selective in-
jury to type 1 and type 2 cells by paraquat itself but also
from the increased permeability of alveolar capillaries fol-
lowing injury to endothelial cells by oxygen radicals [8].
The increased permeability of the alveolocapillary mem-
brane for plasma proteins, leaking from the circulation
into the alveolar space, leads to a further inhibition of the
surfactant function. Finally, this results in a qualitative and
quantitative shortage of pulmonary surfactant at the air-
liquid interface, favouring further accumulation of pro-
tein-rich oedema fluid into the alveolar space.
The hypothesis was proposed, that if surfactant def-
iciency contributed to the pathophysiology of respira-
tory failure in this animal model, then surfactant therapy
should improve gas exchange in animals with respiratory
failure due to paraquat poisoning. First, in one group of
animals the time course of the development of lung injury
after paraquat application was characterized by measure-
ment of gas exchange, lung mechanics and surface tension.
In a second group of animals, we investigated whether
surfactant replacement therapy could improve gas exchange
in rats suffering from severe respiratory failure due to
experimental paraquat poisoning.
Materials and methods
This study was approved by the Animal Use and Care
Committee of the Erasmus University Rotterdam. Female
adult Sprague-Dawley rats (body weight 200–250 g) were
used. The animals were cared for in accordance with the
guidelines of the United States Department of Agricul-
ture.
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ABSTRACT: Paraquat is a weed killer which causes often fatal lung damage in
humans and other animals. There is evidence that the pulmonary surfactant system is
involved in the pathophysiology of respiratory failure after paraquat intoxication
and, therefore, the possible therapeutic effect of intratracheal surfactant administra-
tion on gas exchange in rats with progressive lung injury induced by paraquat poison-
ing was studied.
In one group of rats, the time course of the development of lung injury due to
paraquat intoxication was characterized. In a second group of rats, 72 h after
paraquat intoxication, the animals underwent mechanical ventilation and only those
animals in which the arterial oxygen tension/inspiratory oxygen fraction (Pa,O2/FI,O2)
decreased to below 20 kPa (150 mmHg) received exogenous surfactant (200 mg·kg-1
body weight). 
Within 3 days the rats in group 1 developed progressive respiratory failure, demon-
strated not only by impaired gas exchange and lung mechanics but also by increased
minimal surface tension and increased protein concentration in broncho-alveolar lav-
age fluid.
In group 2, intratracheal surfactant administration increased Pa,O2/FI,O2 signifi-
cantly within 5 min (14.4±2.4 kPa (108±18 mmHg)) to (55.2±5.3 kPa (414±40 mmHg))
and sustained this level for at least 2 h.
It is concluded that intratracheal surfactant administration is a promising
approach in the treatment of severe respiratory failure caused by paraquat poisoning.
Eur Respir J 1998; 12: 284–287.
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The study consisted of two parts. In experiment 1 an
animal model was set up and in experiment 2 the rats
received surfactant replacement therapy.
Experiment 1
The rats (n=48) were randomly divided into two groups:
one group of 12 untreated rats served as controls and the
remaining 36 rats were given a subcutaneous injection of
a 2% aqueous solution of paraquat (Methyl Viologen;
Sigma, London, UK), 35 mg·kg-1 body weight [9]. The
rats receiving paraquat were then divided into three groups
of 12 rats, each group to be killed at days 1, 2 and 3. Each
day, the rats were used for
 in vivo assessment of respira-
tory failure and subsequently the rats were divided into
two groups of 6 rats each. The first group was used for
bronchoalveolar lavage (BAL) analysis, while the second
group was used for the measurement of lung mechanics.
All animals were housed in standard plastic cages, receiv-
ed standard food ad libitum and were weighed at 12 h in-
tervals for 72 h.
Assessment of severity of respiratory failure. The animals
were anaesthetized with nitrous oxide, oxygen and halo-
thane (65%, 33% and 2%), a tracheotomy was performed,
and a catheter was inserted into the carotid artery. The rats
were ventilated with a Servo Ventilator 900C (Siemens
Elema, Solna, Sweden) at the following ventilator settings:
pressure controlled ventilation, inspiratory oxygen fraction
(FI,O2)=1.0, respiratory frequency (fR)=30 breaths·min-1,
airway pressure (Paw)=14 cmH2O and positive end-expira-
tory pressure (PEEP)=2 cmH2O at an inspiratory/expiratory
ratio of 1:2. Anaesthesia was maintained with pentobarbital
sodium (60 mg·kg-1·h-1, i.p.) and muscle relaxation with
pancuronium bromide (0.5 mg·kg-1·h-1, i.m.). After a 5 min
stabilization period, blood samples were taken from the
carotid artery and analysed immediately (ABL 505 Radio-
meter, Copenhagen, Denmark). Subsequently, the Paw was
raised to 26 cmH2O and the PEEP was raised to 6 cmH2O.
Again, arterial blood samples were taken and analysed
after a 5 min stabilization period. Finally, the Paw and
PEEP were reduced back to 14 and 2 cmH2O. The rats
then underwent either bronchoalveolar lavage (BAL)
analysis or measurement of lung mechanics.
Bronchoalveolar lavage. The rat lungs were lavaged twice
with saline (37°C, 30 mL·kg-1 body weight-1) via the intra-
tracheal tube. The animals were then killed with an over-
dose of pentobarbital sodium. The lavage fluid was pooled
and immediately placed on ice. Any lavage fluid foam
was included in the pooled sample. Within 30 min after
the lavage, the lavage fluid was centrifuged at 500×g for 5
min at 4°C to remove the cell pellet. The supernatant was
stored at -70°C until analysis.
Bronchoalveolar lavage analysis. The BAL supernatant
was analysed for surface-active properties and total pro-
tein. The surface tension was measured using a modified
Wilhelmy balance [10] (E. Biegler, Mauerbach, Austria).
Surface activity in BAL fluid was measured by applying
500 µL BAL fluid to the surface of a saline-filled trough
(37°C, trough maximally filled, baseline >70 mN·m-1) and
minimal and maximal surface tensions were recorded after
three cycles (cycle time=3 min). Total protein concentra-
tion was determined in each sample by a modification of
the Lowry method [11] .
Lung mechanics. The anaesthetized animals were killed
by ventilation with pure nitrogen for 15 min. Subsequ-
ently, the thorax was opened and the pressure-volume
characteristics of the lungs in the opened chest were det-
ermined. Pressure-volume relations were recorded by in-
jecting 0.5 mL increments of air
 via a tracheal cannula
up to a maximum pressure of 30 cmH20. Then, 0.5 mL
increments of air were withdrawn from the lungs. After
each change in volume the pressure was allowed to equili-
brate for 15 s. At a pressure of 5 cmH20 the trachea was
clamped. The pressures were recorded with a pressure
transducer (Statham P23XL; Spectramed, Oxnard, CA,
USA) connected to a polygraph (Grass Instrument Co.,
Quincy, MA, USA). From the pressure-volume curve, the
stability index (SI) according to GRUENWALD [12] was calcu-
lated. The lungs (clamped at a pressure of 5 cmH2O to
compensate for loss of intrapleural pressure) were then
removed from the chest cavity and weighed. Total lung
volume was measured by immersion in a liquid-filled
graduated cylinder and the displaced volume was deter-
mined. From these results and the specific gravity of the
lung tissue, the post mortem lung volume at end-expira-
tion (V5), which supposedly approximates the functional
residual capacity (FRC) [13], can be calculated.
Experiment 2
Surfactant therapy. This experiment was performed 72 h
after paraquat intoxication. The anaesthetized rats were
prepared in the same way as described above (see assess-
ment of severity of respiratory failure). They were then ven-
tilated with a Servo Ventilator 900C (Siemens Elema, Solna,
Sweden) at the following ventilator settings: pressure-con-
trolled ventilation, FI,O2=1.0, fR=30·min-1, Paw=26 cmH2O,
PEEP=6 cmH2O and inspiratory/expiratory ratio=1:2. After
a 5 min stabilization period, blood samples were taken
from the carotid artery and analysed (ABL 505 Radio-
meter, Copenhagen, Denmark). The animals were included
in the study if, at a ventilation with Paw=26 cmH2O and
PEEP = 6 cmH2O, the arterial oxygen tension (Pa,O2) did
not exceed 20 kPa (150 mmHg). The animals were ran-
domly divided into three groups: group A (n=11) received
an intratracheal bolus of surfactant (200 mg·kg body
weight-1; 50 mg·mL-1 saline), group B (n=5) received no
treatment at all and group C (n=4) received a bolus of
saline (4 mL·kg-1 body weight). After treatment the venti-
lator settings were left unchanged. Arterial blood samples
were taken at 5, 30, 60, 90 and 120 min post-treatment.
The blood samples were analysed for Pa,O2, arterial car-
bon dioxide tension (Pa,CO2) and pH (ABL 505 Radio-
meter, Copenhagen, Denmark).
Surfactant. A freeze-dried natural pig surfactant prepa-
ration, as described previously [14], was used for the intra-
tracheal surfactant administration. This preparation consists
of approximately 90% phospholipids and 1% hydrophobic
proteins (surfactant protein (SP)-B and SP-C), the remainder
being other lipids (e.g. cholesterol, free fatty acids and
glyceride). Owing to isolation procedures, there is no SP-A
in this preparation. A 50 mg·mL-1 suspension was pre-
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pared by suspending the preparation in a 0.9% sodium
chloride solution.
Statistical analysis. All data are expressed as mean±SEM.
Standard analysis of variance (ANOVA) procedures were
carried out for BAL and lung mechanics parameters. When
significant differences between groups occurred, these
differences were further analysed with the Bonferroni
multiple comparison test. Statistical significance was set
at p<0.05.
Results
Experiment 1
Within 24 h after exposure to paraquat the animals
showed signs of toxicity, including rapid and shallow
breathing. On day 2, two rats died and on day 3 another
two rats died. On day 2, blood gas analyses showed signs
of respiratory insufficiency with a reduced Pa,O2. Figure 1
shows Pa,O2 data at different ventilator pressures. On day
1, blood gases were still within the normal range. On day
2, however, the arterial oxygenation was low when venti-
lated at a Paw=14 cmH2O and PEEP=2 cmH2O but in-
creased when ventilator settings were raised to Paw=26
cmH2O and PEEP=6 cmH2O. On day 3, ventilator settings
of pPaw=26 cmH2O and PEEP=6 cmH2O did not improve
blood gases. Table 1 gives the data on BAL analysis and
lung mechanics. Body weight showed a decrease on day 1
after intoxication, which progresses during the course of
the study. The V5 showed a reduction of almost 50% on
day 1 and stayed low, whereas the SI started to decrease
from day 2. The BAL fluid showed a clear increase in pro-
tein content from day 1 to day 3. Surface activity of the
BAL fluid was reduced on day 1–3 (table 1).
Experiment 2
Twenty of 25 rats matched the preset criteria. Figure 2
clearly shows an immediate significant (p<0.05) improve-
ment in Pa,O2 after surfactant therapy (n=11); this Pa,O2
level was sustained for a 120 min period. The rats receiving
no treatment (n=5) show no change over time, whereas the
rats receiving saline (n=4) show a decrease in Pa,O2 as a
result of the instilled volume. In this latter group, two rats
died during the study.
Discussion
The results of this study are in line with several other
reports [5–7, 15]. We confirmed the suggestion by FISHER et
al. [5] that intra-alveolar oedema is present within 24 h
after paraquat intoxication and that this model is a model
not of primary surfactant synthesis damage, but of sur-
factant inhibition. The increased total protein and raised
Fig. 1.  –  Effect of applying different ventilator settings.    : airway
pressure (Paw)=14 cmH2O, positive end-expiratory pressure (PEEP)=2
cmH2O and inspiratory oxygen fraction (FI,O2)=1.0;       : Paw=26 cmH2O
and PEEP=6 cmH2O. On day 1 n=12, on days 2 and 3 n=10. Pa,O2: arterial
oxygen tension. *: p<0.05 compared with day 1; #: p<0.05 compared with
ventilation at Paw=14 cmH2O and PEEP=2 cmH2O. Presented as means
±SEM.
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Fig. 2.  –  Effect of surfactant replacement therapy on arterial oxygen
tension (Pa,O2), with inspiratory oxygen fraction (FI,O2)=1.0.         :
group A (n=11) received surfactant;           : group B (n=5) received no
treatment; and         : group C (n=4) received saline. Presented as
means±SEM. †: one rat died during the course of the study.
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Table 1.  –  Effect of paraquat on rat lungs on days 1, 2 and 3
Days after paraquat intoxication
Control 1 2 3
Body weight  g
V5  mL·kg body weight-1
Stability index
Recovery  %
Total protein  mg·mL-1
Minimal surface tension  mN·m-1
240±3
27.8±1.5
0.97±0.02
91.6±1.7
0.20±0.01
26.0±1.2
211±3*
19.8±4.3
0.89±0.04
85.5±3.0
0.55±0.07
30.2±2.0
202±4*
13.5±3.3*
0.64±0.10*
92.5±2.8
2.1±0.6*
29.2±1.8
199±5*
16.3±3.3*
0.66±0.09*
92.5±2.8
4.1±0.7*
32.2±1.3*
Values are means±SEM. V5: post mortem lung volume at end-expiration. *: p<0.05, intoxicated animals versus controls,
by standard analysis of variance (ANOVA).
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minimal surface tension at 24 h after intoxication clearly
show that the properties of surfactant in the alveoli are
changing. These findings are supported by the reduction
in V5 and the SI. The intra-alveolar accumulation of oed-
ema can be explained in a number of ways. Firstly,
paraquat accumulates in alveolar type I and II cells, where
cell injury is mediated by the formation of free oxygen
radicals, leading to membrane lipid peroxidation and other
forms of tissue damage [16]. Thus, a quantitative sur-
factant deficiency occurs as a result of destruction of the
surfactant-producing type II cells. Secondly, since para-
quat causes cell damage to the cells that are part of the
alveocapillary membrane, leakage of plasma into the alve-
olar space is likely to occur. Furthermore, oxygen radicals
are known to cause increased vascular permeability [8].
These events explain the massive increase in protein con-
tent of the lavage fluid and the increased minimal surface
tension, indicating the presence of plasma-derived sur-
factant inhibitors.
The main goal of treatment of acute respiratory distress
syndrome (ARDS) is to maintain adequate arterial and tis-
sue oxygenation. This can often be achieved by artificial
ventilation with PEEP and increased inspiratory oxygen
concentration. In the present study, increased ventilatory
airway pressures and PEEP could maintain normal arterial
oxygenation for at least 48 h after paraquat poisoning.
After 72 h, however, this was not sufficient to restore the
Pa,O2 to values within the normal range. This can be
explained by alveolar collapse, resulting from increased
alveolar surface tensions. Higher Paw would be needed to
open up the lungs and a PEEP of 6 cmH2O was not high
enough to prevent end-expiratory collapse. In this situa-
tion surfactant replacement therapy resulted in a direct
improvement in arterial blood gases. The main advantage
of surfactant therapy is that the FI,O2 can be reduced. This
is of great importance, because high inspiratory oxygen
concentrations can enhance paraquat toxicity in both rats
[17] and humans [18].
Currently, the debate continues as to the dose of sur-
factant that should be used in ARDS patients. In this
respect, surfactant inhibition plays a major role and the
aim is to achieve a more favourable surfactant/inhibitor
ratio [19]. This can be done in several ways. Firstly, sur-
factant should be given as early as possible [20] and, sec-
ondly, surfactant should be given in high dosage (titrated)
until blood gases improve.
The findings indicate that, initially, a surfactant-defi-
cient state and resulting hypoxaemia in the acute phase of
paraquat poisoning can be overcome by the application of
PEEP. At a later stage, a higher Paw with PEEP had no
effect. Intratracheal instillation of exogenous surfactant
reduces opening pressure, prevents alveolar collapse and,
combined with ventilatory support, restores gas exchange
almost to normal.
In summary, this study shows that paraquat poisoning in
rats results in a surfactant-deficient state, due to surfactant
inhibition by plasma proteins leaking through the damaged
alveocapillary membrane. Initially, surfactant deficiency
can be treated with respiratory support with high peak air-
way pressures and positive end-expiratory pressure. When
respiratory insufficiency is fully developed, intratracheal
instillation of exogenous surfactant can almost completely
restore gas exchange to normal. It is speculated that sur-
factant administration, as early as possible can break the
vicious circle of surfactant inhibition and diminish the
damaging side-effects of artificial ventilation with high
pressures and high oxygen concentrations.
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